Sol-Gel's EPSOLAY® Approved by Health Canada
Ticker: SLGL · Form: 6-K · Filed: Sep 4, 2025 · CIK: 1684693
| Field | Detail |
|---|---|
| Company | Sol-Gel Technologies Ltd. (SLGL) |
| Form Type | 6-K |
| Filed Date | Sep 4, 2025 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | bullish |
Sentiment: bullish
Topics: regulatory-approval, product-launch, international-market
TL;DR
Health Canada greenlights Sol-Gel's EPSOLAY® for rosacea treatment.
AI Summary
On September 4, 2025, Sol-Gel Technologies Ltd. announced that its product, EPSOLAY®, received approval from Health Canada. This approval allows the company to market EPSOLAY® in Canada for the treatment of inflammatory lesions of the face associated with rosacea.
Why It Matters
This Health Canada approval expands Sol-Gel's market reach for EPSOLAY® into another significant territory, potentially increasing revenue and brand recognition.
Risk Assessment
Risk Level: low — The filing is a routine announcement of regulatory approval, which is generally positive news with limited immediate downside risk.
Key Players & Entities
- Sol-Gel Technologies Ltd. (company) — Registrant
- EPSOLAY® (product) — Product receiving approval
- Health Canada (company) — Regulatory body granting approval
- September 4, 2025 (date) — Date of announcement
FAQ
What is the specific indication for EPSOLAY® in Canada?
EPSOLAY® is approved for the treatment of inflammatory lesions of the face associated with rosacea.
Which regulatory body granted the approval for EPSOLAY®?
Health Canada granted the approval for EPSOLAY®.
What is the filing date of this Form 6-K?
The filing date is September 4, 2025.
What is the principal executive office address of Sol-Gel Technologies Ltd.?
The principal executive offices are located at 7 Golda Meir Street, Ness Ziona 7403650, Israel.
Does Sol-Gel Technologies Ltd. file annual reports under Form 20-F?
Yes, Sol-Gel Technologies Ltd. indicates it files annual reports under Form 20-F.
Filing Stats: 206 words · 1 min read · ~1 pages · Grade level 11.4 · Accepted 2025-09-04 07:00:10
Filing Documents
- zk2533751.htm (6-K) — 9KB
- exhibit_99-1.htm (EX-99.1) — 16KB
- image1.jpg (GRAPHIC) — 17KB
- image00002.jpg (GRAPHIC) — 4KB
- 0001178913-25-003223.txt ( ) — 57KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. SOL-GEL TECHNOLOGIES LTD. Date: September 4, 2025 By: /s/ Eyal Ben-Or Eyal Ben-Or Chief Financial Officer 3